Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, HER negative breast cancer, uterine, pancreatic cancer, urothelial, and non-small-cell lung cancers. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain AVB-500 as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.
IPO Year: 2014
Exchange: NASDAQ
Website: aravive.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/17/2023 | $12.00 | Buy | BTIG Research |
| 6/3/2022 | $15.00 | Buy | ROTH Capital |
SC 13G/A - Aravive, Inc. (0001513818) (Subject)
SC 13G/A - Aravive, Inc. (0001513818) (Subject)
SC 13G/A - Aravive, Inc. (0001513818) (Subject)
SC 13G - Aravive, Inc. (0001513818) (Subject)
SC 13G/A - Aravive, Inc. (0001513818) (Subject)
SC 13D/A - Aravive, Inc. (0001513818) (Subject)
SC 13D/A - Aravive, Inc. (0001513818) (Subject)
SC 13G - Aravive, Inc. (0001513818) (Subject)
SC 13D/A - Aravive, Inc. (0001513818) (Subject)
SC 13D/A - Aravive, Inc. (0001513818) (Subject)
HOUSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), announced today that the Company intends to voluntarily terminate the listing of its common stock on the Nasdaq Global Select Market ("Nasdaq") and, based upon ownership of its shares by fewer than 300 holders of record, deregister its common stock under the Securities Exchange Act of 1934, as amended (the "Exchange Act") and suspend its public reporting obligations. As previously disclosed, at the Company's 2023 annual stockholder's meeting, the stockholders of the Company approved effecting a transfer and assignment of all or substantially all of the Company's assets to an assignee for the benefit
Trial did not meet primary endpoint of progression-free survivalCash at the end of Q2 of approximately $18M (unaudited) is expected to be sufficient to fund operations into early Q4 2023 HOUSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that its Phase 3 AXLerate-OC trial evaluating the safety and efficacy of batiraxcept in platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival (PFS) in the pre-specified subset of patients naïve to prior bevacizumab treatment. The trial did not show any differen
HOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the acceptance of two abstracts for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2023, being held October 20-24, 2023 in Madrid, Spain. Posters will feature clinical data from the Company's ongoing Phase 1b/2 trials of batiraxcept in clear cell renal cell carcinoma (ccRCC) and pancreatic adenocarcinoma (PDAC). Presentation Details: Title:Phase 1b/2 Study of Batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in Combination with Cabozantinib (Cabo)
HOUSTON, July 14, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer will be participating in a fireside chat at the William Blair Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success being held virtually on July 18, 2023. William Blair's Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Format: Fireside Chat with Aravive (ARAV) Date/Time: Tuesday, July 18, 2023 at 12:00-12:45 PM ET Host: Andy Hsieh, Ph.D., Biotech Research Analyst, William Blair
HOUSTON, June 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that in accordance with Nasdaq rules regarding employment inducement awards, the Company has granted an equity compensation award to a new employee. The Compensation Committee of ARAV's Board of Directors approved the award of options to purchase an aggregate of 40,000 shares of common stock, with a grant date of June 8, 2023 (the "Grant Date"), to the newly hired employee in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price of $1.71, the closing pr
HOUSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy Howard, Chief Financial Officer will be presenting a corporate overview and participating in 1x1 meetings at the Jefferies Global Healthcare Conference being held on June 7-9, 2023 in New York, NY. Jefferies Global Healthcare Conference – June 7-9, 2023 Format:Aravive (ARAV) Company Presentation Date/Time:Friday, June 9, 2023 at 8:30 AM EST Session:Track 4 Presenter:Gail McIntyre, Ph.D., DABT, CEO, Aravive Webcast: Regis
HOUSTON, May 25, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of updated results from its ongoing Phase 2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 American Society of Clinical Oncology (ASCO) annual meeting, taking place June 2-6, 2023 in Chicago, IL and virtually. The poster presentation will highlight updated results from the Phase 2 portion of the trial in patients with advanced or metastatic ccRCC with or without prior line(s) of therapy, including immuno-oncology (IO)- and vascular endothelial
Trial initiation anticipated in 2H 2023 with topline data anticipated in 2H 2025Updated Phase 1b/2 ccRCC data to be presented at ASCO 2023 HOUSTON, May 16, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that the Company has received guidance from the U.S. Food and Drug Administration (FDA) on a registrational Phase 3 trial design for batiraxcept in clear cell renal cell carcinoma (ccRCC) at an End-of-Phase 2 (EOP2) meeting. "We are very pleased to be advancing batiraxcept into Phase 3 development in ccRCC, having successfully completed our EOP2 meet
On Track for PROC Pivotal Phase 3 Trial Readout Mid-2023Promising ccRCC Phase 1b/2 Results to Date; Update to be Presented at ASCO 2023Strengthened Management Team with Appointment of Carolina Petrini as Chief Commercial OfficerCompany hosting Key Opinion Leader (KOL) webinar featuring batiraxcept in PROC and ccRCC on May 24, 2023 at 1pm ET; Go to the Company website to register HOUSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported first quarter 2023 financial results and provided corporate updates. "During the first quarter, we continu
HOUSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced it will host a virtual Key Opinion Leader (KOL) event on its late-stage oncology asset, batiraxcept, on Wednesday, May 24, 2023 at 1:00pm ET. The event will feature oncology experts Katherine Fuh, MD, PhD (UCSF Division of Gynecologic Oncology), who will discuss batiraxcept as a potential treatment for ovarian cancer, and Katy Beckermann, MD, PhD (Vanderbilt-Ingram Cancer Center; Vanderbilt University Medical Center), who will provide an overview of batiraxcept as a promising treatment f
HOUSTON, April 11, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of Carolina Petrini as the Company's new Chief Commercial Officer effective April 10, 2023. Ms. Petrini brings over two decades of experience in developing pre-commercial, launch readiness and commercial strategies, building and leading high-performing commercial teams. "We are delighted to welcome Carolina as our new Chief Commercial Officer," said Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive. "With her extensive experience in oncology and exception
Establishment of Strategic Advisory Board provides renowned business development, clinical and regulatory leadership and expertise as iTolerance advances its proprietary technologies enabling tissue, organoid or cell therapy without the need for life-long immunosuppressionMIAMI, FL / ACCESSWIRE / January 23, 2023 / iTolerance, Inc. ("iTolerance" or the "Company"), an early-stage regenerative medicine company developing technologies to enable tissue, organoid or cell therapy without the need for life-long immunosuppression, today announced the formation of its Strategic Advisory Board and appointments of Wayne Pines, Sigurd Kirk, and Dr. Khemraj Hirani as its inaugural members."The establishm
HOUSTON, July 05, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of Dr. Robert B. Geller as Chief Medical Officer. Dr. Geller is a medical oncologist with over 30 years of drug development experience leading all aspects of clinical and medical affairs, including commercialization preparedness and launch of novel therapeutics. Dr. Geller will play a critical role in progressing Aravive's portfolio of programs in ovarian, renal and pancreatic cancers. "Dr. Geller is a great addition to the management team as we near completion of the gl
HOUSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, the "Company"))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of Rudy Howard as Chief Financial Officer, effective today. Vinay Shah has stepped down as CFO for personal reasons but will remain with the Company as an advisor to ensure a smooth transition. "We are pleased to welcome Mr. Howard to our leadership team during this pivotal time for the Company," said Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive. "His financial experience and expertise will be an asset as we continue to grow the organization. On behalf
HOUSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of industry veteran, Scott Dove, Ph.D., as Chief Operating Officer. "We are honored Dr. Dove is bringing his strong industry, drug development, and leadership experience to Aravive," said Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive. "The next 12 months promises to be the most data-rich period in the Company's history. Scott will be pivotal in executing the steady stream of anticipated clinical milestones across each of our three ongoing clinical programs for batirax
HOUSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that the company's Chairman, Fred Eshelman, Pharm.D., through Eshelman Ventures, LLC, agreed to purchase a pre-funded warrant to purchase 4,545,455 shares of the company's common stock at a price of $2.20 per share, which was the consolidated closing bid price of the company's common stock on The Nasdaq Global Select Market on December 31, 2021. The investment strengthens the company's balance sheet by approximately $10.0 million, enhancing the company's financial flexibility and liquidity ahead of multip
HOUSTON, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that Dr. Ray Tabibiazar will be stepping down from the Aravive Board of Directors but will remain an advisor to the company, effective December 31, 2020. This transition will allow Dr. Tabibiazar to focus on a new venture. Dr. Tabibiazar co-founded private Aravive Biologics and served as the Chairman of its board of directors and as President and Chief Executive Officer from its inception to April 2017 and as Executive Chairman from May 2017 until October 2018. During that time, he led Aravive Biologics through a reverse merger
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the appointment of Jay P. Shepard to its Board of Directors, effective immediately. Mr. Shepard will also serve as a member of the Audit Committee. Following the appointment of Mr. Shepard, the Board is now composed of 11 directors, nine of whom are independent. “We are excited to welcome Jay to Ironwood’s Board. Jay is a recognized leader within our industry with nearly three decades of expertise as an accomplished public company CEO and senior executive,” said Julie McHugh, chair of Ironwood’s Board. “We look forward to leveraging Jay’s deep expertise as we seek to further our mission to adva
7 of 16 (44%) patients achieved best overall response of partial responseConfirmed response in 5 of 7 (71%) patients who had at least 16 weeks of follow-up14 of 16 (88%) patients demonstrated tumor decrease from baselineBatiraxcept has been well-tolerated with no dose-limiting toxicitiesConference call and webcast today at 8:30 a.m. ET HOUSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today announced positive new data from the Phase 1b portion of its open-label Phase 1b/2 trial evaluating batiraxcept (AVB-500) in combination with cabozantinib in patie
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baselineBatiraxcept has been generally well-tolerated with no dose-limiting toxicitiesAravive to host conference call and webcast on November 12 at 8:30 a.m. ET to discuss updated data HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today announced that positive new data from the Phase 1b portion of its open-label Phase 1b/2 trial evaluating batiraxcept (AVB-500) in combination with cabozantinib in patients with clear cell renal cell carcinoma (
15-12G - Aravive, Inc. (0001513818) (Filer)
EFFECT - Aravive, Inc. (0001513818) (Filer)
EFFECT - Aravive, Inc. (0001513818) (Filer)
EFFECT - Aravive, Inc. (0001513818) (Filer)
EFFECT - Aravive, Inc. (0001513818) (Filer)
EFFECT - Aravive, Inc. (0001513818) (Filer)
S-8 POS - Aravive, Inc. (0001513818) (Filer)
S-8 POS - Aravive, Inc. (0001513818) (Filer)
S-8 POS - Aravive, Inc. (0001513818) (Filer)
S-8 POS - Aravive, Inc. (0001513818) (Filer)
BTIG Research resumed coverage of Aravive with a rating of Buy and set a new price target of $12.00
ROTH Capital initiated coverage of Aravive with a rating of Buy and set a new price target of $15.00
BTIG Research initiated coverage of Aravive with a rating of Buy and set a new price target of $26.00
BTIG Research initiated coverage of Aravive with a rating of Buy and set a new price target of $26.00
4 - Aravive, Inc. (0001513818) (Issuer)
3 - Aravive, Inc. (0001513818) (Issuer)
4 - Aravive, Inc. (0001513818) (Issuer)
4 - Aravive, Inc. (0001513818) (Issuer)
4 - Aravive, Inc. (0001513818) (Issuer)
4 - Aravive, Inc. (0001513818) (Issuer)
4/A - Aravive, Inc. (0001513818) (Issuer)
4/A - Aravive, Inc. (0001513818) (Issuer)
4 - Aravive, Inc. (0001513818) (Issuer)
4 - Aravive, Inc. (0001513818) (Issuer)